Drug interactions
Erdafitinib + Ertugliflozin-sitagliptin
Severity: Minor
Erdafitinib and Ertugliflozin-sitagliptin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib inhibits P-glycoprotein and may raise exposure to P-gp substrates. Sitagliptin is a P-gp substrate with a wide therapeutic margin, so the increase is unlikely to be clinically important.
What this interaction means in plain words
Erdafitinib and Ertugliflozin-sitagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Erdafitinib belongs to Oncology; Ertugliflozin-sitagliptin belongs to Endocrine.
Why it happens
Erdafitinib inhibits intestinal and renal P-gp efflux, which can increase sitagliptin absorption and reduce its clearance.
What to do
No dose change is usually required; monitor for sitagliptin adverse effects such as hypoglycemia when combined with insulin or sulfonylureas.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erdafitinib and Ertugliflozin-sitagliptin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ertugliflozin-sitagliptin
Other interactions of Erdafitinib
Frequently asked questions
Can I take Erdafitinib with Ertugliflozin-sitagliptin?
MediHelp rates the interaction as minor. Erdafitinib and Ertugliflozin-sitagliptin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Erdafitinib inhibits P-glycoprotein and may raise exposure to P-gp substrates. Sitagliptin is a P-gp substrate with a wide therapeutic margin, so the increase is unlikely to be clinically important.
How serious is the interaction between Erdafitinib and Ertugliflozin-sitagliptin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is usually required; monitor for sitagliptin adverse effects such as hypoglycemia when combined with insulin or sulfonylureas.
What other medicines interact with Ertugliflozin-sitagliptin?
MediHelp also lists interactions of Ertugliflozin-sitagliptin with, for example, Albiglutide, Aripiprazole, Asenapine. The full list is on the Ertugliflozin-sitagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
